Submit Your Opportunity
Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
Search
View from Both Sides of the Table
Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
Boehringer biopharmaceuticals China receives approval supply EU and US
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
founding-member-of-QUTAC
Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
equine asthma
Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
Emmanuelle leads a team of scientists
Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care
Iclepertin: GlyT1 inhibitor
Iclepertin: GlyT1 inhibitor
Early Access Treatments & Compassionate Use Programs
Explore how we facilitate patient access to investigational and/or unlicensed medicines through our individual requests and Compassionate Use programs
CT-155: Prescription digital therapeutic
CT-155: Prescription digital therapeutic
Submit your animal health partnering opportunity
Information on how to submit your animal health innovation opportunity direct to Boehringer Ingelheim’s partnering team
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
SPEVIGO CHMP positive opinion new indications
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
First Translational Medicine Award awarded
The Award recognizes the research that has the highest translational potential
Boehringer expands cancer research at Vienna site
Boehringer Ingelheim expands cancer research at its Vienna site
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
Stroke symptoms
The Angels initiative, stroke symptoms, giving life a chance, optimizing stroke care
The Core of our Leitbild
Who we are and what we strive for